02171.HK
CARsgen Therapeutics Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 13.43
+2.36%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
Market Cap
HKD 7.75B
MomentumView details →
1D Return
+2.36%
YTD Return
−9.56%
RSI (14)
44.6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
Market Cap
HKD 7.75B
RSI (14)
44.6
MomentumView details →
1D Return
+2.36%
YTD Return
−9.56%
Similar companies
Latest newsMore news →
CARsgen Therapeutics announced at its results meeting on August 19, 2026, that Kailimei has been prescribed at Beijing Gaobo Hospital, with cell collection completed at Fudan University-affiliated Zhongshan Hospital and at Jiahui International Cancer Center for a foreign patient.17d agoCARsgen Therapeutics reported interim results for the six months ended June 2026, with revenue of RMB 61.92 million, up 21.5% year-on-year, and a narrowed net loss of RMB 66.66 million, compared with a loss of RMB 75.34 million in the same period last year.17d agoCarsgen Therapeutics announced that its universal CAR-T therapy CT1190B received clinical trial approval from China's National Medical Products Administration for the treatment of relapsed/refractory large B-cell lymphoma.29d ago